Bristol-Myers Squibb Co. is an international biopharmaceutical company established more than 100 years ago, in 1887. Initially, the company produced cough medicines, laxatives, and toothpaste.

Nowadays, the company specializes in the production of medicines for the treatment of cancer, HIV, as well as other serious diseases.

In 2019, the firm was absorbed by the Celgene company, which became one of the largest deals in the field at a total sum of $74 billion.

At the moment, the market cap of Bristol-Myers Squibb Co. totals $151.8 billion. The company’s revenue for 2021 came at $46.39 billion, whereas the net profit was $6.994 billion.

Shares of Bristol-Myers Squibb Co. and factors influencing them

The company’s stocks are traded on the New York Stock Exchange under the ticker of BMY.

Currently, shares of Bristol-Myers Squibb Co. are hovering within the range of $69-$71. During the year, the share price has been changing from $53 to $81.

When trading this asset, pay attention to the following factors:

Bristol-Myers Squibb Co. mainly cooperates with large wholesale companies and distributors and not directly with medical institutions, pharmacies, etc;
Research and new developments play a key role, but it takes a lot of time, on average about 14 years, and requires considerable spending;
The company has joint ventures and projects with other firms in this field;
The company's competitive advantages are features of its products, the effectiveness of marketing, and research work on new products.